NMIBC Risk Calculators. How Useful Are They for the Practicing Urologist and How Can Their Clinical Utility Be Improved?

Urologic Clinics of North America

Volumn 40, Issue 2, 2013, Pages 155-164

  Lammers, Rianne J M ^a   Sylvester, Richard J ^b   Lee, Cheryl T ^c   Witjes, J Alfred ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EORTC Headquarters ^*  (Belgium)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

EORTC; Non muscle invasive bladder cancer; Prognostic model; Risk table

Indexed keywords

BCG VACCINE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; TUMOR MARKER;

ARTIFICIAL NEURAL NETWORK; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; FGFR3 GENE; FUZZY SYSTEM; GENE; GENE MUTATION; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; LOW RISK POPULATION; MEDICAL SOCIETY; NOMOGRAM; NON MUSCLE INVASIVE BLADDER CANCER; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TOTAL QUALITY MANAGEMENT; TRANSURETHRAL RESECTION; UROLOGIST;

DISEASE PROGRESSION; FORECASTING; HUMANS; MODELS, STATISTICAL; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK ASSESSMENT; URINARY BLADDER NEOPLASMS; UROLOGY;

EID: 84876725066     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2013.01.002     Document Type: Review

References (51)

1. Wu X., Ros M.M., Gu J., et al. Epidemiology and genetic susceptibility to bladder cancer. BJU Int 2008, 102(9 Pt B):1207-1215.
2. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
3. Zeegers M.P., Tan F.E., Dorant E., et al. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 2000, 89(3):630-639.
4. Pelucchi C., Bosetti C., Negri E., et al. Mechanisms of disease: the epidemiology of bladder cancer. Nat Clin Pract Urol 2006, 3(6):327-340.
5. Messing E.M. Urothelial tumors of the bladder. Campbell-walsh urology 2007, vol. 9:2419-2431. Saunders Elsevier, Philadelphia. 9th edition.
6. Kirkali Z., Chan T., Manoharan M., et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005, 66(6 Suppl 1):4-34.
7. Sauter G., Algaba F., Amin M.B., et al. Tumours of the urinary system: non-invasive urothelial neoplasias. WHO classification of classification of tumors of the urinary system and male genital organs 2004, 29-34. IARC Press, Lyon (France). J.N. Eble, G. Sauter, J.I. Epstein (Eds.).
8. Sobin L.H., Gospodariwicz M., Wittekind C. Urinary bladder. TNM classification of malignant tumors. UICC Union International Contre le Cancer 2009, vol. 7:262-265. Wiley-Blackwell, Hoboken (NJ).
9. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49(3):465-477.
10. Hernandez V., De La Pena E., Martin M.D., et al. External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer. World J Urol 2011, 29(4):409-414.
11. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011, 59(6):997-1008.
12. Hall M.C., Chang S.S., Dalbagni G., et al. Guideline for the management of non muscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007, 178(6):2314-2330.
13. Sylvester R.J. How well can you actually predict which non-muscle-invasive bladder cancer patients will progress?. Eur Urol 2011, 60(3):431-433. [discussion: 433-4].
14. Sakano S., Matsuyama H., Takai K., et al. Risk group stratification to predict recurrence after transurethral resection in Japanese patients with stage Ta and T1 bladder tumours: validation study on the European Association of Urology guidelines. BJU Int 2011, 107(10):1598-1604.
15. Seo K.W., Kim B.H., Park C.H., et al. The efficacy of the EORTC scoring system and risk tables for the prediction of recurrence and progression of non-muscle-invasive bladder cancer after intravesical bacillus Calmette-Guerin instillation. Korean J Urol 2010, 51(3):165-170.
16. van Rhijn B.W., Zuiverloon T.C., Vis A.N., et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 2010, 58(3):433-441.
17. Pillai R., Wang D., Mayer E.K., et al. Do standardised prognostic algorithms reflect local practice? Application of EORTC risk tables for non-muscle invasive (pTa/pT1) bladder cancer recurrence and progression in a local cohort. ScientificWorldJournal 2011, 11:751-759.
18. Fernandez-Gomez J., Madero R., Solsona E., et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables. Eur Urol 2011, 60:423-430.
19. Kiemeney L.A., Witjes J.A., Heijbroek R.P., et al. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993, 150(1):60-64.
20. Millan-Rodriguez F., Chechile-Toniolo G., Salvador-Bayarri J., et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000, 164(3 Pt 1):680-684.
21. Shariat S.F., Zippe C., Ludecke G., et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 2005, 173(5):1518-1525.
22. Hong S.J., Cho K.S., Han M., et al. Nomograms for prediction of disease recurrence in patients with primary Ta, T1 transitional cell carcinoma of the bladder. J Korean Med Sci 2008, 23(3):428-433.
23. Yamada T., Tsuchiya K., Kato S., et al. A pretreatment nomogram predicting recurrence- and progression-free survival for nonmuscle invasive bladder cancer in Japanese patients. Int J Clin Oncol 2010, 15(3):271-279.
24. Pan C.C., Chang Y.H., Chen K.K., et al. Constructing prognostic model incorporating the 2004 WHO/ISUP classification for patients with non-muscle-invasive urothelial tumours of the urinary bladder. J Clin Pathol 2010, 63(10):910-915.
25. Shapur N., Pode D., Katz R., et al. Predicting the risk of high-grade bladder cancer using noninvasive data. Urol Int 2011, 87(3):319-324.
26. Fernandez-Gomez J., Madero R., Solsona E., et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 2009, 182(5):2195-2203.
27. Catto J.W., Abbod M.F., Linkens D.A., et al. Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. Clin Cancer Res 2009, 15(9):3150-3155.
28. Gakis G., Todenhofer T., Renninger M., et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int 2011, 108(11):1800-1805.
29. Morgan T.M., Keegan K.A., Barocas D.A., et al. Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. J Urol 2011, 186(3):829-834.
30. Shariat S.F., Chromecki T.F., Cha E.K., et al. Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. J Urol 2012, 187(2):457-462.
31. Sonpavde G., Khan M.M., Svatek R.S., et al. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. BJU Int 2011, 108(5):687-692.
32. Sonpavde G., Khan M.M., Svatek R.S., et al. Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. J Urol 2011, 185(4):1216-1221.
33. Taylor J.M., Feifer A., Savage C.J., et al. Evaluating the utility of a preoperative nomogram for predicting 90-day mortality following radical cystectomy for bladder cancer. BJU Int 2012, 109(6):855-859.
34. Rosevear H.M., Lightfoot A.J., Nepple K.G., et al. Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guerin plus interferon-alpha. J Urol 2011, 185(1):67-71.
35. Sylvester R.J. Natural history, recurrence, and progression in superficial bladder cancer. ScientificWorldJournal 2006, 6:2617-2625.
36. Steyerberg E.W. Clinical prediction models. A practical approach to development, validation, and updating 2009, vol. 1. Springer Science, New York.
37. Chamie K., Saigal C.S., Lai J., et al. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer 2011, 117(23):5392-5401.
38. Elstein A.S. Heuristics and biases: selected errors in clinical reasoning. Acad Med 1999, 74(7):791-794.
39. Fowler F.J., McNaughton Collins M., Albertsen P.C., et al. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 2000, 283(24):3217-3222.
40. Ross P.L., Gerigk C., Gonen M., et al. Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol 2002, 20(2):82-88.
41. Specht M.C., Kattan M.W., Gonen M., et al. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol 2005, 12(8):654-659.
42. Brausi M., Witjes J.A., Lamm D., et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 2011, 186(6):2158-2167.
43. Schrier B.P., Hollander M.P., van Rhijn B.W., et al. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 2004, 45(3):292-296.
44. Hollenbeck B.K., Dunn R.L., Ye Z., et al. Delays in diagnosis and bladder cancer mortality. Cancer 2010, 116(22):5235-5242.
45. Skolarus T.A., Ye Z., Montgomery J.S., et al. Use of restaging bladder tumor resection for bladder cancer among Medicare beneficiaries. Urology 2011, 78(6):1345-1349.
46. Shariat S.F., Margulis V., Lotan Y., et al. Nomograms for bladder cancer. Eur Urol 2008, 54(1):41-53.
47. Shariat S.F., Karakiewicz P.I., Ashfaq R., et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008, 112(2):315-325.
48. Riester M., Taylor J.M., Feifer A., et al. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res 2012, 18(5):1323-1333.
49. van Rhijn B.W., Liu L., Vis A.N., et al. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. BJU Int 2012, 110:1169-1176.
50. Sylvester R.J. Combining a molecular profile with a clinical and pathological profile: biostatistical considerations. Scand J Urol Nephrol Suppl 2008, (218):185-190.
51. Vickers A.J., Cronin A.M. Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework. Semin Oncol 2010, 37(1):31-38.